Fig. 1From: Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort studyKaplan-Meier survival curves for PFS (A) and OS (B) among patients treated with afatinib. PFS, progression-free survival; OS, overall survivalBack to article page